Eli Lilly raises price of Mounjaro obesity drug
Digest more
2don MSN
Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
It comes as President Donald Trump pressures drugmakers to lower U.S. drug prices while hiking them abroad under a policy called "most favored nation."
Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise
Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no margin for competitive disruption.
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Click here to read an analysis of LLY stock now.
Pharma giant Eli Lilly said it is negotiating to raise drug prices in Europe, starting in the U.K. with the weight-loss drug Mounjaro, so that it can comply with the Trump administration’s goal of bringing down prices in the U.S.
We recently published 10 Stocks On Jim Cramer’s Radar Including Big Tech Firms. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed.
Eli Lilly (LLY) stock recovers as company executives seize a rare buying opportunity to make a series of insider purchases following a sharp selloff. Read more here.
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.
Eli Lilly partners with the Indiana Fever and YMCA to empower girls in basketball, removing barriers and promoting community engagement in sports.
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.
Eli Lilly is eligible for 100M in tax credits to expand its Pleasant Prairie facility, adding 750 jobs and boosting Wisconsin s biotech manufacturing sector.
Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.